November 12, 2006

Brand Name Invega Chosen for Schizophrenia Drug, Paliperidone

Janssen, L.P., a wholly owned subsidiary of Johnson & Johnson (J&J), announced that it has selected INVEGA™ as the brand name for its investigational oral atypical antipsychotic, paliperidone extended release tablets. Once-daily Invega is being touted by the company as a follow-up drug to its other antipsychotic, Risperdal. J&J's patent on Risperdal expires in December 2007.

The company is seeking approval from the U.S. Food and Drug Administration (FDA) to market INVEGA™ for the treatment of schizophrenia.

J&J Press Release: Janssen, L.P., Selects INVEGA™ (Paliperidone) Extended Release Tablets as Brand Name for Its Investigational Atypical Antipsychotic

Additional Reading:
Paliperidone - J&J Schizophrenia Drug, Gets Conditional Approval


Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required